Tamoxifen: A synthetic overview

Current Organic Chemistry

Volumn 16, Issue 3, 2012, Pages 335-352

  Kasiotis, Konstantinos M ^a   Haroutounian, Serkos A ^b  

^a BENAKI PHYTOPATHOLOGICAL INSTITUTE   (Greece)

^b AGRICULTURAL UNIVERSITY OF ATHENS   (Greece)

Author keywords

Antiestrogen; Breast cancer; Carbometallation; Organometallic nucleophiles; SERM; Tamoxifen

Indexed keywords

CANCER CELLS; CATALYSTS; DISEASES; KETONES; TRANSITION METALS;

ANTI-ESTROGENS; BREAST CANCER; BREAST CANCER CELLS; CARBOMETALLATION; ESTROGEN RECEPTOR; ORGANOMETALLIC NUCLEOPHILE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TRIPHENYLETHYLENE; TUMORIGENESIS;

ORGANOMETALLICS;

EID: 84857740048     PISSN: 13852728     EISSN: None     Source Type: Journal    
DOI: 10.2174/138527212799499886     Document Type: Review

References (67)

1. Beatson, G.T. On the treatment of inoperable cases carcinogen of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet, 1896, 2, 105-107.
2. Suwandi, L.S.; Agoston, G.E.; Shah, J.H.; Hanson, A.D.; Zhan, X.H.; Lavallee, T.M.; Treston, A.M. Synthesis and antitumor activities of 3- modified 2-methoxyestradiol analogs. Bioorg. Med. Chem. Lett., 2009, 19, 6459-6462.
3. Yaya, A.R.; Touaibia, M.; Massarweh, G.; Rochon, F.D.; Breau, L. Synthesis of 17 alpha-substituted ethynylestradiols: potential ligands for drug vectors. Steroids, 2010, 75, 489-498.
4. Kasiotis, K.M.; Magiatis, P.; Pratsinis, H.; Skaltsounis, A.; Abadji, V.; Charalambous, A.; Moutsatsou, P., Haroutounian, S.A. Synthesis and biological evaluation of novel daunorubicin-estrogen conjugates. Steroids, 2001, 66, 785-791.
5. Kasiotis, K.M.; Mendorou, C.; Haroutounian, S.A.; Alexis, M.N. High affinity 17alpha-substituted estradiol derivatives: synthesis and evaluation of estrogen receptor agonist activity. Steroids, 2006, 71, 249-255.
6. Wakeling, A.E.; Dukes, M.; Bowler, J. A potent specific pure antiestrogen with clinical potential. Cancer. Res., 1991, 51, 3867-3873.
7. Robertson, J.F.; Come, S.E.; Jones, S.E.; Beex, L.; Kaufmann, M.; Makris, A.; Nortier, J.W.; Possinger, K.; Rutqvist, L.E. Endocrine treatment options for advanced breast cancer--the role of fulvestrant. Eur. J. Cancer, 2005, 41, 346-356.
8. Buijs, C.; de Vries, E.G.; Mourits, M.J.; Willemse, P.H. The influence of endocrine treatments for breast cancer on health-related quality of life. Cancer Treat. Rev., 2008, 34, 640-655.
9. Dodds E.C. Acta Med. Scand. Suppl., 1938, 90, 141.
10. Musa, M.A., Khan, M.O.F., Cooperwood, J.S. Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs). Curr. Med. Chem., 2011 14, 1249-1261.
11. Rosano, C., Stec-Martyna, E., Lappano, R., Maggiolini, M. Structure-Based Approach for the Discovery of Novel Selective Estrogen Receptor Modulators. Curr. Med. Chem., 2011, 18, 1188-1194.
12. Miller C.P. SERMs: Evolutionary chemistry, revolutionary biology. Curr. Pharm. Design, 2002, 8, 2089-2111.
13. Ray, S., Sangita. The potent triaryiethylene pharmacophore. Drugs of the Future, 2004, 29, 185-203.
14. Lewis, J.S.; Jordan, V.C. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat. Res., 2005, 591, 247-263.
15. Jordan, V.C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. Part 1. Receptor interactions. J. Med. Chem., 2003, 46, 883-908.
16. Jordan, V.C. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. Part 2. Clinical considerations and new agents J. Med. Chem., 2003, 46, 1081-1111.
17. Jordan, V.C. Tamoxifen. Comprehensive Medicinal Chemisrty II 2007, 8, 83-102.
18. Jordan, V.C. Tamoxifen: A most unlikely pioneering medicine. Nat. Rev. Drug Discov. 2003, 2, 205-213.
19. Haroutounian, S.A.; Scribner, A.W.; Katzenellenbogen, J.A. Derivatives of 4-styrylpyridines: synthesis, estrogen receptor binding affinity, and photophysical properties. Steroids, 1995, 60, 636-645.
20. Ruenitz, P.C.; Bourne, C.S.; Sullivan, K.J.; Moore, S.A. Estrogenic triarylethylene acetic acids: effect of structural variation on estrogen receptor affinity and estrogenic potency and efficacy in MCF-7 cells. J. Med. Chem., 1996, 39, 4853-4859.
21. Lubczyk, V.; Bachmann, H.; Gust, R. Investigations on estrogen receptor binding. The estrogenic, antiestrogenic, and cytotoxic properties of C2-alkylsubstituted 1,1-bis(4-hydroxyphenyl)-2-phenylethenes. J. Med. Chem., 2002, 45, 5358-5364.
22. Lubczyk, V.; Bachmann, H.; Gust, R. Antiestrogenically active 1,1,2-tris(4- hydroxyphenyl)alkenes without basic side chain: synthesis and biological activity. J Med. Chem., 2003, 46, 1484-1491.
23. Rubin, V.N.; Ruenitz, P.C.; Boudinot, F.D.; Boyd, J.L. Identification of new triarylethylene oxyalkanoic acid analogues as bone selective estrogen mimetics. Bioorg. Med. Chem., 2001, 9, 1579-1587.
24. Rubin, V.N.; Ruenitz, P.C.; Boyd, J.L.; Boudinot, F.D., Wiese, T.E. Characterization of selective estrogen receptor modulator (SERM) activity in two triarylethylene oxybutyric acids. Biochem. Pharmacol., 2002, 63, 1517-1525.
25. Nguyen, A.; Top, S.; Pigeon, P.; Vessieres, A.; Hillard, E.A.; Plamont, M.A.; Huche, M.; Rigamonti, C., Jaouen, G. Synthesis and structure-activity relationships of ferrocenyl tamoxifen derivatives with modified side chains. Chemistry, 2009, 15, 684-696.
26. Nguyen, A.; Top, S.; Vessières, A.; Pigeon, P.; Huché, M.; Hillard, E.A.; Jaouen, G. Organometallic analogues of tamoxifen: Effect of the amino sidechain replacement by a carbonyl ferrocenyl moiety in hydroxytamoxifen. J. Organomet. Chem., 2007, 692, 1219-1225.
27. Pickar, J.H., MacNeil, T., Ohleth, K. SERMs: Progress and future perspectives. Maturitas, 2010, 67, 129-138.
28. Zhou, W.B., Ding, Q., Chen, L., Liu, X.A., Wang, S. Toremifene is an effective and safe alternative to tamoxifen in adjuvant endocrine therapy for breast cancer: results of four randomized trials. Breast Cancer Res.Treat., 2011, 128, 625-631.
29. Hulka, B.S. Epidemiology of susceptibility to breast cancer. Prog. Clin. Biol. Res., 1996, 395, 159-174.
30. Ingle, J.N. Estrogen as therapy for breast cancer. Breast Cancer Res., 2002, 4, 133-136.
31. Eisen, A.; Trudeau, M.; Shelley, W.; Messersmith, H.; Pritchard, K.I. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. Cancer Treat. Rev., 2008, 34, 157-174.
32. Monnier, A. Adjuvant trials: Aromatase inhibitors in early breast cancer-are they alike? Cancer Treat. Rev., 2006, 32, 532-540.
33. Vogel, V.G.; Costantino, J.P.; Wickerham, D.L.; Cronin, W.M.; Cecchini, R.S.; Atkins, J.N.; Bevers, T.B.; Fehrenbacher, L.; Pajon, E.R. Jr.; Wade, J.L., 3rd; Robidoux, A.; Margolese, R.G.; James, J.; Lippman, S.M.; Runowicz, C.D.; Ganz, P.A.; Reis, S.E.; McCaskill-Stevens, W.; Ford, L.G.; Jordan, V.C.; Wolmark, N. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA, 2006, 295, 2727-2741.
34. Harper, M.J.; Walpole, A.L. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature, 1966, 212, 87.
35. Robertson, D.W.; Katzenellenbogen, J.A.; Long, D.J.; Rorke, E.A.; Katzenellenbogen, B.S. Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. J. Steroid. Biochem., 1982, 16, 1-13.
36. Fauq, A.H., Maharvi, G.M., Sinha, D. A convenient synthesis of (Z)-4- hydroxy-N-desmethyltamoxifen (endoxifen). Bioorg. Med. Chem. Lett., 2010, 20, 3036-3038.
37. Ali, S.M., Ahmad, A., Shahabuddin, S., Ahmad, M.U., Sheikh, S., Ahmad, I. Endoxifen is a new potent inhibitor of PKC: A potential therapeutic agent for bipolar disorder. Bioorg. Med. Chem. Lett., 2010, 20, 2665-2667.
38. Dodds, C.E.; Fitzgerald, M.E.H.; Lawson, W. Estrogenic activity of some hydrocarbon derivatives of ethylene. Nature, 1940, 140, 772.
39. Robson, J.M.; Schönberg, A. Oestrous reactions including mating produced by triphenylethylene. Nature, 1937, 140, 196.
40. Bedford, G.R.; Richardson, D.N. Preparation and Identification of cis and trans Isomers of a Substituted Triarylethylene. Nature, 1966, 212, 733-734.
41. Collins, D.J.; Hobbs, J.J.; Emmens, C.W. Antiestrogenic and antifertility compounds. 4. 1,1,2-Triarylalkan-1-ols and 1,1,2-Triarylalk-1-enes containing basic ether groups. J. Med. Chem., 1971, 14, 952-957.
42. Robertson, D.W.; Katzenellenbogen, J.A. Synthesis of the E and Z isomers of the antiestrogen Tamoxifen and it's metabolite, 4-Hydroxytamoxifen. J. Org. Chem., 1982, 47, 2387-2393.
43. McCague, R. Stereoselective Olefin formation from the dehydration of 1-Cp- (Alkoxyphenyl)-1,2,-diphenylbutan-1-ols: Application to the Synthesis of Tamoxifen. J. Chem. Soc. Perkin Trans. 1 1987, 1011-1015.
44. Jarman, M.; McCague, R. The use of octafluorotoluene and pentafluoropyridine in the synthesis of pure Z and E isomers of tamoxifen. J. Chem. Res., 1985, (S) 116-117 (M) 1342-1388.
45. McCague, R. The use of the perfluorotolyl protecting group in the synthesis of pure Z- and E-isomers of 4-hydroxytamoxifen. J. Chem. Res., 1986, 58-59 miniprint 771-793.
46. Olier-Reuchet, C.; Aitken, D.J.; Bucourt, R.; Husson, H.-P. Synthesis of tamoxifen and 4-hydroxytamoxifen using super-base metalated propylbenzene. Tet. Lett., 1995, 36, 8221-8224.
47. Coe, P.L.; Scriven, C.E. Crossed coupling of functionalised ketones by low valent titanium (the McMurry reaction): a new stereoselective synthesis of tamoxifen. J. Chem. Soc. Perkin Trans. 1, 1986, 475-477.
48. Detsi, A.; Koufaki, M.; Calogeropoulou, T. Synthesis of (Z)-4- hydroxytamoxifen and (Z)-2-[4-[1-(p-hydroxyphenyl)-2-phenyl]- 1butenyl]phenoxyacetic acid. J. Org. Chem., 2002, 67, 4608-4611.
49. Yu, D.D.; Forman, B.M. Simple and efficient production of (Z)-4- hydroxytamoxifen, a potent estrogen receptor modulator. J. Org. Chem., 2003, 68, 9489-9491.
50. Miller, R.B.; Al-Hassan, M.J. Stereospecific synthesis of (z)-tamoxifen via carbometalation of alkynylsilane. J. Org. Chem., 1985, 50, 2121-2123. and references therein.
51. Miller, R.B.; Al-Hassan, M.J. A highly stereoselective synthesis of 1-halo-1- (trimethylsilyl)-2,2-dialkyl olefins. J. Org. Chem., 1984, 49, 725-726. and references therein.
52. Tessier, P.E.; Penwell, A.J.; Souza, F.E.; Fallis, A.G. (Z)-tamoxifen and tetrasubstituted alkenes and dienes via a regio- and stereospecific threecomponent magnesium carbometalation palladium(0) cross-coupling strategy. Org. Lett., 2003, 5, 2989-2992.
53. Pilli, R.A.; Robello, L.G. Palladium-catalyzed double cross-coupling of Evinylic dibromides with PhZnCl and the synthesis of tamoxifen. J. Braz. Chem. Soc., 2004, 15, 938-944.
54. Stüdemann, T.M.; Ibrahim-Ouali, M.; Knochel, P. A nickel catalyzed carbozincation of aryl-substituted alkynes. Tetrahedron, 1998, 54, 1299-1316.
55. Stüdemann, T.M.; Knochel, P. A nickel catalyzed carbozincation of alkynes: A short synthesis of (Z)-tamoxifen. Angew. Chem. Int. Ed. Engl., 1997, 36, 93-95.
56. Al-Hassan, M.J. Synthesis of cis- and trans-tamoxifen. Synth. Commun., 1987, 17, 1247-1251.
57. Tanigushi, N. Copper catalyzed synthesis of β-haloalkenyl chalcogenides by addition of dichalcogenides to internal alkynes and its application to synthesis of (Z)-tamoxifen. Tetrahedron, 2009, 65, 2782-2790.
58. Nunes, C.M.; Limberger, J.; Poersch, S.; Seferin, M.; Monteiro, A.L. Trans- Stilbene as a starting material for the synthesis of tamoxifen based on palladium- catalyzed cross-coupling reactions. Synthesis 2009, 16, 2761-2765.
59. Itami, K.; Kamei, T., Yoshida, J. Diversity-oriented synthesis of tamoxifentype tetrasubstituted olefins. J. Am. Chem. Soc., 2003, 125, 14670-14671.
60. Shimizu, K.; Takimoto, M.; Mori, M., Sato, Y. Effective synthesis of tamoxifen using nickel-catalyzed arylative carboxylation. Synlett, 2006, 18, 3182-3184.
61. Cummins, C.H. Stereospecific synthesis of clomiphene and tamoxifen via stannylcupration of diphenylacetylene. Synth. Commun., 1995, 25, 4071-4079
62. Shiina, I.; Suzuki, M., Yokoyama, K. Short-step synthesis of tamoxifen and itsderivatives via the three-component coupling reaction and migration of the double bond. Tet. Lett., 2004, 45, 965-967.
63. Winkler, V.W.; Nyman, M.A., Egan, R.S. Diethylstilbestrol cis-trans isomerization and estrogen activity of diethylstilbestrol isomers. Steroids, 1971, 17, 197-207.
64. Shiina, I.; Sano, Y.; Nakata, K.; Suzuki, M.; Yokoyama, T.; Sasaki, A.; Orikasa, T.; Miyamoto, T.; Ikekita, M.; Nagahara, Y.; Hasome, Y. An expeditious synthesis of tamoxifen, a representative SERM (selective estrogen receptor modulator), via the three-component coupling reaction among aromatic aldehyde, cinnamyltrimethylsilane, and beta-chlorophenetole. Bioorg. Med. Chem., 2007, 15, 7599-7617.
65. Yus, M.; Ramón, D.J.; Gómez, I. Preparation of β, n-dilithiotoluene equivalents. Synthesis of tamoxifen. Tetrahedron, 2003, 59, 3219-3225.
66. Pandey, R.K.; Wakharkar, R.D.; Kumar, P. Wittig-Horner approach for the synthesis of tamoxifen. Synth. Commun., 2005, 35, 2795-2800.
67. Brown, D.S.; Armstrong, R.W. Parallel synthesis of tamoxifen and derivatives on solid support via resin capture. J. Org. Chem., 1997, 62, 7076-7077.